PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers-Reference-Cited by-同舟云学术

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers

Published:2017-11-29 Issue:1 Volume:4 Page:
ISSN:2053-6844
Container-title:Gynecologic Oncology Research and Practice
language:en
Short-container-title:gynaecol oncol res pract

Author:

Sisay Mekonnen^ORCID,Edessa Dumessa

Funder

No funding

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s40661-017-0055-8.pdf

Reference68 articles.

1. Liu JF, Matulonis UA. What is the place of PARP inhibitors in ovarian cancer treatment? Curr Oncol Rep. 2016;18(5):29.

2. Rabenau K, Hofstatter E. DNA damage repair and the emerging role of poly (ADP-ribose) polymerase inhibition in cancer therapeutics. Clin Ther. 2016;38(7):1577–88.

3. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071.

4. Zhang J. Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer. Asian J Androl. 2014;16(3):401–6.

5. Dantzer F, de la Rubia G, Ménissier-de Murcia J, Hostomsky Z, de Murcia G, Schreiber V. Base excision repair is impaired in mammalian cells lacking poly (ADP-ribose) polymerase-1. Biochemistry. 2000;39(25):7559–69.

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis;Journal of Chemotherapy;2024-08-23

2. Genetic and Epigenetic Biomarkers Associated with Early Relapse in Pediatric Acute Lymphoblastic Leukemia: A Focused Bioinformatics Study on DNA-Repair Genes;Biomedicines;2024-08-05

3. Atherosclerosis Is a Smooth Muscle Cell–Driven Tumor-Like Disease;Circulation;2024-06-11

4. Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors;Cancer Chemotherapy and Pharmacology;2023-11-27

5. The potential of PARP as a therapeutic target across pediatric solid malignancies;BMC Cancer;2023-04-05